



Figure 1




= SOLID SUPPORT

R = TERMINAL PROTECTING GROUP
FOR EXAMPLE:
DIMETHOXYTRITYL (DMT)

(1) = CLEAVABLE LINKER
(FOR EXAMPLE: NUCLEOTIDE SUCCINATE OR
INVERTED DEOXYABASIC SUCCINATE)
(2) = CLEAVABLE LINKER
(FOR EXAMPLE: NUCLEOTIDE SUCCINATE OR
INVERTED DEOXYABASIC SUCCINATE)



INVERTED DEOXYABASIC SUCCINATE
LINKAGE



GLYCEROL SUCCINATE LINKAGE

Figure 2




Figure 3






Figure 4



POSITIONS (NN) CAN COMPRISE ANY NUCLEOTIDE, SUCH AS DEOXYNUCLEOTIDES
(eg. THYMIDINE) OR UNIVERSAL BASES
B = ABASIC, INVERTED ABASIC, INVERTED NUCLEOTIDE OR OTHER TERMINAL CAP
THAT IS OPTIONALLY PRESENT
L = GLYCERYL MOIETY THAT IS OPTIONALLY PRESENT
S = PHOSPHOROTHIOATE OR PHOSPHORODITHIOATE

Figure 5



lower case = 2'-O-Methyl or 2'-deoxy-2'-fluoro
italic lower case = 2'-deoxy-2'-fluoro
underline = 2'-O-methyl

ITALIC UPPER CASE = DEOXY
B = INVERTED DEOXYABASIC
L = GLYCERYL MOIETY OPTIONALLY PRESENT
S = PHOSPHOROTHIOATE OR
PHOSPHORODITHIOATE

Figure 6




Figure 9: Target site Selection using siRNA





Figure 10



R = O, S, N, alkyl, substituted alkyl, O-alkyl, S-alkyl, alkaryl, or aralkyl
 B = Independently any nucleotide base, either naturally occurring or chemically modified, or optionally H (abasic).

Figure 11: Modification Strategy




Figure 12 : siRNAs targeting HCV chimera







Figure 13: HCV siRNA dose response



**Figure 14: Chemically Modified siRNA targeting
HCV chimera**



**Figure 15: Chemically Modified siRNA targeting
HCV chimera**



**Figure 16: Chemically Modified siRNA targeting
HCV chimera**




Figure 17: Chemically Modified siRNA
targeting HCV chimera

HCV/PV#280-siRNA to HCV-Luc site 325/345







Figure 18: HCV/Replicon KJ#1-Clone A Cells transfected
with 0.5µl/well LFA 2K-72 hours




**Figure 19: Dose Response with Stab4/5 siNA Leads
in HCV Subgenomic Replicon**



**Figure 20: Activity of Stab 7/8 siNA Leads in HCV
Subgenomic Replicon**



**Figure 21: Dose Response with Fully Modified
HCV Site 327 siNA**



**Figure 22: Activity of siNA/Interferon
Combination Treatment in HCV Replicon**






Figure 23: Phosphorylated siNA constructs



Phosphates can be modified
as described herein



Asymmetric duplex
siNA

